EFFICACY OF TIGECYCLINE TREATMENT IN SEVERE AND
COMPLICATED CLOSTRIDIUM DIFFICILE INFECTION
LILIANA MIREA1,2#, CORNELIA NIȚIPIR2,3#*, IOANA CRISTINA GRINȚESCU1#, ALEXANDRU BĂETU1#, RALUCA GÎNGU4#, ANDREEA LETIȚIA ARSENE5#, IOANA MARINA GRINȚESCU1,2#
1Intensive Care Clinic, Clinical Emergency Hospital of Bucharest, Romania
2“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3Department of Oncology and Radiotherapy, Elias Emergency University Hospital, Bucharest, Romania
4Department of Microbiology, Clinical Emergency Hospital of Bucharest, Romania
5“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of General and Pharmaceutical
Microbiology, Bucharest, Romania
*corresponding author: nitipir2003@yahoo.com
#All authors had equally contributed to this article.
DownloadDownload Full Article

Abstract:
The aim of this study was to analyse the efficacy of tigecycline compared with the standard therapy (vancomycin plus
metronidazole) in adults treated for severe Clostridium difficile infection (sCDI). A retrospective cohort study of septic
patients, with at least one organ dysfunction and sCDI, hospitalized at Intensive Care Unit of the Clinical Emergency
Hospital of Bucharest, Romania, from January to December 2016, was performed. Patients receiving tigecycline plus
standard therapy, early or later in the course of the infection, were compared with the standard therapy alone. Outcomes were
the clinical recovery, 30-day mortality and complications rate. There were no statistical differences between the groups
regarding demographic data, severity score and comorbidity index. The introduction of tigecycline as tardive treatment does
not show any major improvement, but survival rate increased from 12.1% with standard therapy to 80% with early
administration of tigecycline, without any adverse reactions attributable to tigecycline. Favourable outcomes suggest that
tigecycline could be an additional option for treatment of sCDI, but it requires further larger trial studies for support.






Top